Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers

NCT ID: NCT00800579

Last Updated: 2009-10-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-11-30
• Study Completion Date: 2009-02-28

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of escalating doses of GS-9411 in healthy male volunteers. GS-9411 is a sodium channel inhibitor, that may restore airway hydration and mucociliary clearance in the lung.

Detailed Description

GS-9411 is being evaluated as a potential therapy to improve airway hydration and mucociliary clearance in patients with cystic fibrosis. This study is evaluating the safety and tolerability of 3 dose levels of GS-9411 as an inhaled product, compared to a matched placebo.

Conditions

Cystic Fibrosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

1

GS-9411 0.6 mg

Group Type: EXPERIMENTAL

GS-9411

Intervention Type: DRUG

Inhaled GS-9411 dissolved in sterile saline

2

GS-9411 1.2 mg

Group Type: EXPERIMENTAL

GS-9411

Intervention Type: DRUG

Inhaled GS-9411 dissolved in sterile saline

3

GS-9411 2.4 mg

Group Type: EXPERIMENTAL

GS-9411

Intervention Type: DRUG

Inhaled GS-9411 dissolved in sterile saline

4

Inhaled volume-matched sterile saline placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Inhaled volume-matched placebo in sterile saline

Interventions

GS-9411

Inhaled GS-9411 dissolved in sterile saline

Intervention Type: DRUG

Placebo

Inhaled volume-matched placebo in sterile saline

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Males 18 to 45 years of age.
• No clinically important abnormal physical findings at screening.
• No clinically relevant abnormal lab results at screening.
• Normal (or abnormal but not clinically significant) ECG.
• Normal (or abnormal but not clinically significant) blood pressure (BP) and heart rate (HR).
• Body weight between 70 and 125 kg and body mass index (BMI) between 18 and 28 kg/m2, or outside range, but not clinically significant and agreed with sponsor and principal investigator.
• Able to communicate well with the investigator and to comply with the requirements of the entire study.
• Provision of written informed consent.
• Non-smokers of at least 6 months duration (< 10 pack year history) prior to study entry.
• Negative for drugs of abuse (including alcohol) at Screening and Day -5.
• Must be willing to abstain from alcohol and strenuous exercise during the 48-hour period prior to admission and while confined to the clinic.
• Forced expiratory volume in 1 second (FEV1) greater than or equal to 80% of predicted normal for age, gender, and height as per Hankinson et al1 at Screening and Pre-dose.
• Normal intraocular pressure between 10 and 22 mmHg.
• Male subjects who are sexually active must be willing to use effective barrier contraception (e.g., condom) during heterosexual intercourse from Baseline/Day 0 through completion of the study and continuing for at least 30 days from date of last dose of study drug.
• Male subjects must refrain from sperm donation from Day 1 through completion of the study and continuing for at least 30 days from the date of last dose of study drug.

Exclusion Criteria

• Administration of any investigational drug in the period 0 to 12 weeks before entry to the study.
• A need for any medication during the period 0 to 5 days before entry to the study, except those deemed by the principal investigator/clinical investigator not to interfere with the outcome of the study.
• Existence of any surgical or medical condition which, in the judgment of the clinical investigator, might interfere with the absorption, distribution, metabolism, or excretion of the drug.
• Presence or history of allergy requiring treatment. Hay fever is allowed unless it is active or has required treatment within the previous 2 months.
• Donation or loss of greater than 400 mL of blood in the period 0 to 12 weeks before entry to the study.
• Serious adverse reaction or hypersensitivity to any drug.
• Presence or history of any pulmonary diseases (e.g., asthma, emphysema, chronic bronchitis, cystic fibrosis, bronchiectasis).
• Consumption of drugs and/or herbal preparations capable of inducing hepatic enzyme metabolism (e.g., barbiturates, rifampicin, carbamazepine, phenytoin, primidone, or St. John's Wort) or enzyme-inhibiting agents (e.g., cimetidine) or similar drugs within 30 days (or 5 half-lives of inducing/inhibiting agent, whichever is longer) of enrollment in this study.
• Major surgery within 6 months of the start of this study.
• Subjects who have experienced a significant upper or lower respiratory tract infection within the 6 weeks prior to admission.
• Subjects with significant history of respiratory, renal, hepatic, cardiovascular (including history of systemic hypertension requiring therapy), metabolic, neurological, hematological, gastrointestinal, cerebrovascular, or other significant medical illness or disorder which, in the judgment of the investigator, may interfere with the study or require treatment which may affect the evaluation of efficacy and safety of the study drug.
• Subjects with elevated liver enzyme concentrations.
• Haemoglobin level < 130 g/L taken at Screening and at Pre-dose.
• Plasma potassium > 5 mEq/L taken at Screening and at Pre-dose.
• Poor venous access.
• Intraocular pressure > 21 mm Hg

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Gilead Sciences

INDUSTRY

Sponsor Role: lead

Responsible Party

Gilead Sciences, Inc.

Principal Investigators

Peter Hodsman, MD

Role: PRINCIPAL_INVESTIGATOR

Nucleus Network Ltd

Locations

Nucleus Network Ltd.

Melbourne, Victoria, Australia

Countries

Australia

Other Identifiers

GS-US-221-0101

Identifier Type: -

Identifier Source: org_study_id